357 related articles for article (PubMed ID: 26344626)
1. Therapeutic Vaccine Strategies against Human Papillomavirus.
Khallouf H; Grabowska AK; Riemer AB
Vaccines (Basel); 2014 Jun; 2(2):422-62. PubMed ID: 26344626
[TBL] [Abstract][Full Text] [Related]
2. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.
Skeate JG; Woodham AW; Einstein MH; Da Silva DM; Kast WM
Hum Vaccin Immunother; 2016 Jun; 12(6):1418-29. PubMed ID: 26835746
[TBL] [Abstract][Full Text] [Related]
3. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
Mahdavi A; Monk BJ
Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
[TBL] [Abstract][Full Text] [Related]
4. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
5. Vaccination to prevent and treat cervical cancer.
Roden RB; Ling M; Wu TC
Hum Pathol; 2004 Aug; 35(8):971-82. PubMed ID: 15297964
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Vaccines Against Human Papilloma Viruses: Achievements and Prospects.
Vonsky MS; Runov AL; Gordeychuk IV; Isaguliants MG
Biochemistry (Mosc); 2019 Jul; 84(7):800-816. PubMed ID: 31509730
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
Cheng MA; Farmer E; Huang C; Lin J; Hung CF; Wu TC
Hum Gene Ther; 2018 Sep; 29(9):971-996. PubMed ID: 29316817
[TBL] [Abstract][Full Text] [Related]
10. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy.
Santin AD; Bellone S; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Curr Pharm Des; 2005; 11(27):3485-500. PubMed ID: 16248803
[TBL] [Abstract][Full Text] [Related]
12. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.
Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y
Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192
[TBL] [Abstract][Full Text] [Related]
13. Different spectra of therapeutic vaccine development against HPV infections.
Bolhassani A; Mohit E; Rafati S
Hum Vaccin; 2009 Oct; 5(10):671-89. PubMed ID: 19684468
[TBL] [Abstract][Full Text] [Related]
14. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
Bartkowiak T; Singh S; Yang G; Galvan G; Haria D; Ai M; Allison JP; Sastry KJ; Curran MA
Proc Natl Acad Sci U S A; 2015 Sep; 112(38):E5290-9. PubMed ID: 26351680
[TBL] [Abstract][Full Text] [Related]
15. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
16. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
[TBL] [Abstract][Full Text] [Related]
17. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.
Vandepapeliere P; Barrasso R; Meijer CJ; Walboomers JM; Wettendorff M; Stanberry LR; Lacey CJ
J Infect Dis; 2005 Dec; 192(12):2099-107. PubMed ID: 16288373
[TBL] [Abstract][Full Text] [Related]
20. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
Peng S; Qiu J; Yang A; Yang B; Jeang J; Wang JW; Chang YN; Brayton C; Roden RBS; Hung CF; Wu TC
Cell Biosci; 2016; 6():16. PubMed ID: 26918115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]